Life Sciences
Overview
On June 1, 2025, Crowell & Moring LLP and Faber Daeufer & Itrato combined to establish Crowell Life Sciences. This team, distinguished by deep industry and government experience, provides companies, academic research institutions, and investors in the life sciences ecosystem with integrated and industry-leading transactional, regulatory, intellectual property, and litigation counsel.
Crowell Life Sciences brings together Faber’s leading life sciences-focused venture finance, R&D transactional, and complex licensing and development agreements practice, with Crowell’s strengths in health care regulatory, government contracting, international trade, data privacy, patent prosecution, and health care and IP litigation, positioning the team to provide clients with solution-oriented guidance in a dynamic business environment.
Crowell Life Sciences is uniquely comprised of former in-house lawyers and business executives in biopharma, private fund professionals, and contract specialists from pharmaceutical companies and contract research organizations.
The team delivers pragmatic corporate and transactional counsel to life sciences companies from start-up through commercialization, to investment firms, to academic research institutions, and to NGOs involved in the discovery, development, manufacture, and commercialization of novel therapeutics, devices, and research tools aided by emerging AI and in silico technologies.
As life sciences companies and investors advance mission-critical strategies at a time of rapid change and economic uncertainty, Crowell is well-positioned to provide valuable industry and government insight.
Whether it’s cross-border engagement with investors and business and scientific partners, U.S. and EU regulatory compliance, new tariff regimes, supply chain disruption or export controls, Crowell Life Sciences supports clients as they navigate increased complexity in designing R&D and go-to-market strategies along with a myriad of IP and data protection challenges, including global patent prosecution. Across the lifecycle of life sciences businesses, clients benefit from the well-integrated business, legal, and government experience of Crowell Life Sciences.
Industry Know How
- Launching a drug development company
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity - while our licensing professionals have drafted and negotiated countless agreements securing intellectual rights to foundational technologies.
- Getting ready for a phase 2 or 3 clinical trial
Our experienced contracts specialists work alongside attorneys steeped in the business side of life sciences.
- Establishing a pharmaceutical supply chain
Our team of professionals understand the industry-specific drivers of complex supply chains.
Contacts
Representative Matters
Tasca Therapeutics Corp.
Series A Financing
Tasca Therapeutics launches with $52 million in Series A financing co-led by Regeneron Ventures and Cure Ventures, and with participation by Invus Group.
2024
EvolveImmune Therapeutics, Inc. + AbbVie
Collaboration and License Agreement
EvolveImmune Therapeutics in a collaboration and option-to-license agreement with AbbVie to develop multispecific biologics for multiple targets in oncology leveraging EvolveImmune’s T-cell engager platform, with an upfront payment of $65 million, up to $1.4 billion in option fees and milestones, as well as tiered royalty payments on net sales.
2024
Ananda Scientific, Inc.
Investigator-Initiated Clinical Trial Agreement
Counsel to Ananda Scientific in collaboration with Yale School of Medicine to conduct investigator initiated clinical trial evaluating Nantheia™ ATL5 for use in treating co-occurring opioid use disorder (OUD) and chronic pain. The study will be led by Principal Investigator Joao P. De Aquino, M.D.
2024
GV Management Company, LLC
PeopleOne Health Series B Financing
Representation of GV Management Company as lead in PeopleOne Health’s $32.3M Series B Financing.
2024
Novo Nordisk A/S
Asset Purchase Agreement and Grant-Back License Agreement
Counsel to Novo Nordisk in acquisition of 2seventy’s Hemophilia A program and rights to MegaTAL in vivo gene editing technology.
2024
NextPoint Therapeutics, Inc.
Series B Financing - Extension
NextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint subsequently raises $42.5M in an extension to its Series B led by Catalio Capital Management, bringing the total raised to $122.5M. Additional investors in the round include MPM BioImpact, Invus, Sixty Degree Capital, Binney Street Capital, and Arkin Bio-Capital.
2024
GV Management Company, LLC
Series B Financing
Representation of GV Management Company, as lead, and a16z Bio + in Santa Ana Bio’s $125M Series B Financing. Other investors included TPG, Access Biotechnology, and RTW.
2024
Claris Biotherapeutics, Inc.
Series A-3 preferred stock financing
Claris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors.
2024
GV Management Company, LLC
Chroma Medicine Series B Financing
Representation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing.
2023
Paragon Therapeutics, Inc.
Discovery and Option Agreement
Option for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions.
2022
Epalex Corporation
Series A-3 Financing
Series A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs.
2022
Contacts
Insights
Professionals
Partner
|He/Him/His
